Clinical spectrum and prognostic impact of cancer in critically ill patients with HIV: a multicentre cohort study
An erratum to this article was published (Ann Intensive Care, 14 Feb 2024 ↗)
Authors' conclusion
NADC and ADC are equally prevalent, stand as a leading argument for TLD, and strongly predict in-hospital death in the current population of PLHIV requiring ICU admission.
Study context
- Population
- People living with HIV (PLHIV) admitted to 12 university-affiliated intensive care unit (ICUs) in France, 2015–2020PLHIV
- Participants
- 939 participants
- Exposure
- Active NADC or active ADC vs no cancer
- ADCn = 106
- NADCn = 97
- Outcome
- In-hospital mortality
Methodological details12 university-affiliated ICUs
- 12 university-affiliated ICUs
Main finding
As reported in the abstract
Each group vs no cancerAdjusted odds ratio (95% CI)
NADC
7.00(4.07–12.05)
ADC
3.11(1.76–5.51)
Observational data: associations, not effects.
Further findings
Treatment limitation decision (TLD) during ICU stay
One-year mortality in survivors of index hospital admission (exploratory)
- Treatment limitation decision (TLD) during ICU stay: P < 0.0001
- One-year mortality in survivors of index hospital admission (exploratory): P < 0.0001
Treatment limitation decision (TLD) during ICU stay
- Organ failures and non-neoplastic comorbidities less often considered in patients with cancer
Original publication
Clinical spectrum and prognostic impact of cancer in critically ill patients with HIV: a multicentre cohort study. Ann Intensive Care. Published 22 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →